Ransom Advisory Ltd Increases Stock Position in Eli Lilly and Company $LLY

Ransom Advisory Ltd increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 112.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,451 shares of the company's stock after acquiring an additional 1,300 shares during the quarter. Eli Lilly and Company makes up about 0.8% of Ransom Advisory Ltd's holdings, making the stock its 29th biggest position. Ransom Advisory Ltd's holdings in Eli Lilly and Company were worth $1,870,000 as of its most recent SEC filing.Get Eli Lilly and Company alerts:3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the MostA number of other large investors have also recently bought and sold shares of LLY. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at about $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new position in Eli Lilly and Company in the 2nd quarter valued at about $27,000. Evolution Wealth Management Inc. acquired a new position in Eli Lilly and Company in the 2nd quarter valued at about $29,000. Steph & Co. raised its stake in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company's stock valued at $30,000 after acquiring an additional 29 shares during the last quarter. Finally, Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $31,000. Institutional investors and hedge funds own 82.53% of the company's stock. Wall Street Analyst Weigh InLLY has been the topic of a number of recent research reports. Sanford C. Bernstein boosted their target price on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an "outperform" rating in a report on Monday, November 24th. UBS Group boosted their price objective on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a "buy" rating in a research note on Friday, November 7th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Eli Lilly and Company in a report on Monday. Finally, Daiwa America raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Tuesday. Four analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $1,141.73.Pfizer Adds to Its Big Bet on Weight Loss DrugsView Our Latest Stock Report on LLYEli Lilly and Company Price PerformanceShares of NYSE LLY opened at $1,042.06 on Thursday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The firm has a market capitalization of $985.14 billion, a P/E ratio of 50.98, a PEG ratio of 1.32 and a beta of 0.37. The company's fifty day moving average is $951.95 and its two-hundred day moving average is $826.51. Golden Cross Alert: 3 Stocks With Major Upside PotentialEli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts' expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business's revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year. Eli Lilly and Company Increases DividendThe company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company's dividend payout ratio is presently 29.35%. About Eli Lilly and Company (Free Report)Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.Featured StoriesFive stocks we like better than Eli Lilly and CompanyHow to Use High Beta Stocks to Maximize Your Investing ProfitsPost 35% Surge, Analysts Eye More Upside in Copper Giant Freeport2 Rising CRM Platform Stocks That Can Surge Higher in 2025 Why a SpaceX IPO Could Be a Major Catalyst for GOOGL StockStock Splits, Do They Really Impact Investors?Can Upwork Maintain Its Comeback? Reasons to Be Bullish and BearishWant to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Eli Lilly and Company Right Now?Before you consider Eli Lilly and Company, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.While Eli Lilly and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here